Pune-based Gennova Biopharmaceuticals which has been developing India's first mRNA COVID-19 vaccine has submitted phase 2 data of its candidate HGCO19 and has also completed the recruitment of phase 3 data.

Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) is expected to review the data soon.

Gennova Biopharmaceuticals has also developed the mRNA vaccine for the Omicron variant that will be tested on humans for efficacy and immunogenicity starting in February.

Read more at https://www.indiatimes.com/news/india/indias-first-mrna-covid-19-va...